Yinhui Zeng

Yinhui Zeng

Auto-generated profile, based on publicly available information

Yinhui Zeng

Department of Otolaryngology, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2024 in Iranian Journal of Allergy, Asthma and Immunology
Verified
Journal Article
Closed access
YLYan Li
Yan Li
HXHaiqing Xiao
Haiqing Xiao
YZYinhui Zeng
Yinhui Zeng
YTYiquan Tang
Yiquan Tang
LZLifeng Zhou
Lifeng Zhou
WLWenlong Liu
Wenlong Liu
Allergen-specific immunotherapy (AIT) has confirmed its efficacy in improving the symptoms of allergic rhinitis. However, no reliable biomarkers have been identified to predict the efficacy of AIT were found. We aimed to find clinical and immunological markers to predict efficacy in children after 2 years of sublingual immunotherapy (SLIT). A total of 285 children diagnosed with allergic rhinitis were recruited. The clinical efficacy was evaluated by comparing endpoint and baseline symptom and medication scores (SMS). Baseline clinical and immunological markers (serum total and specific immunoglobulin [Ig]E) and their correlation with clinical efficacy were analyzed. Of the 285 children recruited, 249 completed the 2-year SLIT program. After 2 years of SLIT, 68.3% of the children showed a significant response. Children in the Remarkable Response Group had the highest baseline SMS and most extended disease duration, followed by the Effective Relief and Unresponsive Group. Correlation analysis demonstrated that SMS improvement was positively correlated with baseline SMS (r=0.67) and disease duration (r=0.35). SMS improvement was not correlated with age, body mass index, total or specific IgE levels, or their ratios. Our results show that baseline SMS and disease duration can predict the efficacy of SLIT. Our study can guide the selection of suitable candidates for SLIT.

11 May 2022 in Allergy, Asthma & Clinical Immunology
Verified
Journal Article
Open access
PDF file
SGShengli Gao
Shengli Gao
QZQingxiang Zeng
Qingxiang Zeng
YZYinhui Zeng
Yinhui Zeng
YTYiquan Tang
Yiquan Tang
WLWenlong Liu
Wenlong Liu
Background: More and more studies had suggested that dyslipidemia was closely related to allergic diseases. High density lipoprotein (HDL) often plays anti-inflammatory and anti-oxidative roles by suppressing immune cell chemotaxis and activation. We aimed to explore the role of HDL in the regulation of group II innate lymphoid cells (ILC2) in allergic rhinitis (AR). Methods: The blood lipid levels and their correlation with symptom scores of 20 AR subjects and 20 controls were analyzed. Purified ILC2 were stimulated by HDL and cytokines production were examined by enzyme-linked immunosorbent assay (ELISA) and flow cytometry. The mRNA levels of GATA binding protein 3(GATA3) and retinoid-related orphan receptor α (RORα) expressed by ILC2 were detected using reverse transcription polymerase chain reaction (RT-PCR). Results: HDL level was significantly lower in AR than controls and correlated with the symptom scores. The serum HDL levels were negatively related to the increased number of ILC2, IL-5+ ILC2, and IL-13+ ILC2 in AR patients. HDL decreased the number of ILC2 and type II cytokines levels significantly by inhibiting expression of GATA3 and RORα. Conclusions: Our data provide preliminary evidence that HDL may play a negative role in ILC2 inflammation in AR, suggesting that HDL may serve as promising treatment target in AR.

16 January 2025 in Mediators of Inflammation
Verified
Journal Article
Open access
YZYinhui Zeng
Yinhui Zeng
TLTing Lin
Ting Lin
WXWanhua Xie
Wanhua Xie
SGShengli Gao
Shengli Gao
QZQingxiang Zeng
Qingxiang Zeng
WLWenlong Liu
Wenlong Liu
Background: Although numerous studies have focused on diagnostic biomarkers to help identify allergic rhinitis (AR), data on the characteristics of pediatric AR with different severity is limited. We aimed to compare the characteristics of pediatric AR with different severity. Methods: A total of 1054 children with AR were enrolled and classified into mild intermittent AR, mild persistent AR, moderate‐to‐severe intermittent AR, and moderate‐to‐severe persistent AR. All children were surveyed using a questionnaire that included detailed demographic information. Blood cell analysis was performed using an automatic hematology analyzer. Results: No significant differences were observed in feeding patterns, dietary habits, outdoor activity time, total IgE, eosinophil count, and eosinophil percentage among the different AR subgroups. However, a higher prevalence of a family history of AR was noted in the moderate‐to‐severe persistent group. Symptoms were more likely to exacerbate when using air conditioning in children with moderate‐to‐severe persistent AR. Multivariate regression analysis also showed that symptom exacerbation when using air conditioning was associated with disease severity. Conclusions: This study suggests that exacerbation of symptoms during air conditioning use can be considered a predictive factor for the severity of pediatric AR. Doctors and parents should pay special attention to these children to prevent more severe symptoms and improve the quality of life of these patients as early as possible.

14 April 2023 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
QZQingxiang Zeng
Qingxiang Zeng
YZYinhui Zeng
Yinhui Zeng
HXHaiqing Xiao
Haiqing Xiao
JLJinyuan Li
Jinyuan Li
CYChao Yang
Chao Yang
YWYanhui Wen
Yanhui Wen
Background. Interleukin-37b is a fundamental inhibitor of innate and acquired immunity. Type 2 innate lymphoid cells (ILC2s) can secret type 2 cytokines and regulate allergic rhinitis (AR). However, the role of IL-37b in ILC2s in children with AR was not clear. Methods. We recruited 15 AR children and controls. The serum IL-37b levels and its relation with the frequency and functional phenotype of ILC2s. The regulation of IL-37b on ILC2s proliferation and function was confirmed using flow cytometry and enzyme-linked immunosorbent assay (ELISA). The mRNA expression of IL-1R8, IL-18Rα, and ICOSL was examined using RCR. The change of IL-37b protein level in serum during subcutaneous allergen immunotherapy (SCIT) was determined by ELISA. Results. We have demonstrated that both of the frequencies of blood ILC2s, IL-5+ILC2s, and IL-13+ILC2s in AR children were elevated compared with controls. The serum protein level of IL-37b was downregulated in AR, and it was negatively related to the frequency of ILC2s, IL-5+ILC2s, and IL-13+ILC2s. IL-37b increased the mRNA levels of IL-1R8, IL-18Rα, and ICOSL expressed by ILC2s. IL-37b suppressed the proliferation of ILC2s and the secretion of IL-5 and IL-13 from ILC2s. Finally, we found that IL-37b was increased in AR children after 3 years SLIT, especially in the good response group. Conclusion. Our findings highlight the role of IL-37b in the suppression of ILC2s and establish a new therapeutic target in AR.

3 June 2022 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
WLWenlong Liu
Wenlong Liu
QZQingxiang Zeng
Qingxiang Zeng
YZYinhui Zeng
Yinhui Zeng
YTYiquan Tang
Yiquan Tang
RLRenzhong Luo
Renzhong Luo
Background. Allergic rhinitis (AR) is the most frequent inflammatory disorder in the nasal mucosa that remains unclear etiology. Mounting studies suggested that genetic instability could trigger and worsen the inflammatory response. The nucleotide excision repair (NER) system is an important pathway in maintaining the stability of the genome. Therefore, the genetic variations in NER pathway genes may have potential effects on AR risk. Methods. We evaluated the correlation between 19 candidate single nucleotide polymorphisms (SNPs) in NER pathway genes and AR susceptibility by a case-control study in a Chinese population, which contains 508 AR cases and 526 controls. Results. Three independent SNPs were identified as significantly associated with AR susceptibility, including ERCC1 rs2298881 (recessive model: adjusted odds ratios , , ), ERCC1 rs11615 (dominant model: ,

28 February 2025 in Iranian Journal of Allergy, Asthma and Immunology
Verified
Journal Article
Closed access
XCXi Chen
Xi Chen
WLWenxing Liu
Wenxing Liu
XGXiaohua Guo
Xiaohua Guo
YZYinhui Zeng
Yinhui Zeng
XSXingrong Song
Xingrong Song
WLWenlong Liu
Wenlong Liu
Propofol, a quick‑acting systemic anesthetic agent widely used in general anesthesia, can alleviate airway T-helper 2 (TH2) inflammation. Group 2 innate lymphoid cells (ILC2s) are a newly discovered group of lymphoid cells and play key roles in allergic rhinitis (AR). We aimed to investigate the regulation of ILC2s treated with propofol and its possible mechanisms in a mouse model. An ovalbumin (OVA)-sensitized and challenged mouse model was established. Nasal lavage fluid (NLF) and tissue samples were collected for the detection of inflammatory cells, type II cytokines, and ILC2s using Giemsa staining, enzyme-linked immunosorbent assay, and flow cytometry. CD4+ T cells and ILC2s were cocultured and detected by flow cytometry to confirm the proportion of TH2 cells. Compared with OVA-sensitized and challenged mice, propofol-treated model mice presented decreased type II cytokine levels and total numbers of cells, eosinophils, neutrophils, and macrophages in NLF. Mice treated with propofol presented decreased nasal ILC2 frequency. Moreover, the nasal expression of GATA binding protein 3 (GATA3) and retinoid-related orphan receptor α (RORα), as well as the levels of IL-5 and IL-13, were significantly inhibited after propofol treatment. Compared with those cultured alone, cocultures of ILC2s and CD4+ T cells resulted in significantly more TH2 cells. When propofol was added, the percentage of TH2 cells significantly decreased. This effect was alleviated when anti-major histocompatibility complex class II (anti-MHC II) protein was added. Our study provides preliminary evidence that propofol can play an inhibitive role in AR by regulating innate and adaptive immunity.